QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 springworks-therapeutics-has-completed-the-submission-of-a-new-drug-application-to-the-fda-for-mirdametinib-for-pediatric-and-adult-patients-with-neurofibromatosis-type-1--associated-plexiform-neurofibromas

In the second half of 2024, SpringWorks also plans to file a Marketing Authorization Application (MAA) with the European Medici...

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 hc-wainwright--co-reiterates-buy-on-springworks-therapeutics-maintains-74-price-target

HC Wainwright & Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and maintains $74 ...

 springworks-therapeutics-q1-2024-gaap-eps-118-misses-116-estimate-sales-21006m-beat-12206m-estimate

SpringWorks Therapeutics (NASDAQ:SWTX) reported quarterly losses of $(1.18) per share which missed the analyst consensus estima...

 hc-wainwright--co-maintains-buy-on-springworks-therapeutics-raises-price-target-to-74

HC Wainwright & Co. analyst Robert Burns maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Buy and raises the pric...

 jp-morgan-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-74

JP Morgan analyst Anupam Rama maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

 barclays-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-63

Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...

 wedbush-maintains-outperform-on-springworks-therapeutics-raises-price-target-to-70

Wedbush analyst David Nierengarten maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Outperform and raises the price t...

 barclays-maintains-overweight-on-springworks-therapeutics-raises-price-target-to-47

Barclays analyst Peter Lawson maintains SpringWorks Therapeutics (NASDAQ:SWTX) with a Overweight and raises the price target...